CE Credit Information
Learning Objectives
- Integrate clinical best practices that will aid the provider to deliver the best patient outcomes.
- Establish a clear, successful OSD treatment approach for a range of disease states based on scientific data and expert opinion.
- Develop a practical approach to inspiring and leading a well-informed OSD treatment team.
- Describe key clinic flow guidelines in OSD Clinic.
- Summarize current and future OSD diagnostic technology and how to use it to inform clinical decision-making.
- Outline about currently available and pipeline OSD treatments and where to incorporate them.
- Define how specialty contact lenses can successfully be incorporated into the OSD treatment strategy.
- Describe treatment options for OSD patients with glaucoma and other ocular co-morbid conditions.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Fundingsland Group and Twin Cities Ocular Surface Disease Symposium. The Fundingsland Group is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Fundingsland Group designates this live activity for a maximum of 13 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Sponsored By:
The Fundingsland Group, LLC is a COPE-Approved Administrator.
This activity, COPE Activity Number 128842, is accredited by COPE for continuing education for optometrists. This course is approved for 13.0 hours of CE.
Course #:
91879-TD
91912-TD
91913-TD
91916-TD
91917-TD
91918-TD
91920-TD
91922-TD
91923-TD
91924-TD
Activity #: 128842
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Grant Support Statement
Workshop B, Demodex Blepharitis, Ocular Mucosal Irrigation, Lacrimal Dilation and Irrigation, Punctal Occlusion, is partially supported by an unrestricted educational grant from Tarsus Pharmaceuticals, Inc.
Participation Method
To claim credit, attendees must scan the QR Code for each course prior to the start of the session, remain for the duration of the course, and complete the course evaluation online. Scanning the code verifies attendance into the attendee’s CE tracker account. Twin Cities OSD will then provide a hard copy certification with their attended sessions listed on location.
Financial Relationship Disclosures
It is the policy of The Fundingsland Group (TFG) that faculty and other individuals who are in a position to control the content of this activity disclose all financial relationships they have with COPE-defined ineligible companies in the last 24 months.
All relevant financial relationships were mitigated.
Ahmad Fahmy, OD, Program Chair, has disclosed the following relevant financial relationships: Consultant/Speaker: BioSciences, Dompe, Sight Sciences, Tarsus, Viatris, and Vital Tears.
Damon Dierker, OD has disclosed the following relevant financial relationships: Advisory Board: Aerie, Avellino, Azura, Carl Zeiss Meditec, Genentech, Immunogen, Ocuphire, OcuTerra. Advisory Board/Consultant: Quidel, Thea. Advisory Board/Consultant/Speaker: Alcon, Eyevance, Glaukos, Kala, MacuLogix, Novartis, RVL Pharmaceuticals, Shire. Advisory Board/Consultant/Speaker/Research: Allergan, Bio-Tissue, Notal Vision, Oyster Point, Sight Sciences, Tarsus. Advisory Board/Research: Ocular Therapeutix. Advisory Board/Speaker: Bausch & Lomb, Sun Pharma. Co-Founder/Consultant: Eyes on Eyecare. Consultant: NovaBay, Scope. Consultant/Chief Medical Officer: TearLab. Consultant/Chief Medical Officer Optometry: Trukera Medical. Consultant/Speaker: Johnson & Johnson, Lumenis, ScienceBased Health. Research: ArcticDx, Gyroscope. Speaker: Apellis, MacuHealth, Optovue, Osmotica.
David Hardten, MD has disclosed the following relevant financial relationships: Consultant: Sightpath. Speaker: Dompe, ESI, Glaukos, Johnson & Johnson.
Hardeep Kataria, OD has disclosed the following relevant financial relationships: Consultant/Speaker: BioTissue, Sight Sciences. Consultant: Lumenis, Inmode. Speaker: Alcon, Dompe, Viatris.
Jacob Lang, OD has disclosed the following relevant financial relationships: Consultant/Speaker: Dompe, Oyster Point, Sun Pharma. Consultant: Alcon, Aldeyra, Allergan, AOS, Ascuela Tech, Avellino, Envision Biomedical, Horizon, Carl Zeiss Meditec, Kala, Novartis, Orasis, ScienceBased Health, Scope, Sight Sciences, Tarsus, Thea, Trukera.
Laura Periman, MD has disclosed the following relevant financial relationships: Advisory Board/Consultant/Speaker/Research: Alcon, Bausch & Lomb, Kala, Novartis, Olympic Ophthalmics. Advisory Board, Consultant, Speaker: Allergan, Myze, Nusight Medical, Science Based Health, Scope, Sun, ThermaMed, Visant. Advisory Board/Consultant/ Research: Tarsus. Advisory Board/Consultant: Amgen, Azura. Advisory Board/Speaker: Eyedetec, Mallinckrodt, Versea. Consultant/Speaker/Research: Lumenis. Speaker/ Research: Viatris. Advisory Board: Bruder, Dompe. Consultant: Aldeyra. Speaker: Quench Method.
TFG staff and planners have no financial relationships with ineligible companies.
Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.
Disclaimer
The objective of TFG in developing continuing medical education activities is to promote the free expression and interchange of ideas and information for educational purposes. TFG does not accept responsibility for any opinions, positions, or statements contained or expressed in such material, and such opinions, positions and statements are not necessarily those of the TFG. Courses are intended to provide instruction leading to new knowledge and/or skills. TFG does not certify competence upon completion of the courses. The information presented is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Our Common Goal
“Improving the quality of life of our patients by achieving the best treatment outcomes.”